Tofogliflozin

CAS : 903565-83-3

Ref. 3D-FT28301

Informations sur le produit

• Nom: Tofogliflozin
• Synonymes: (1S,3'R,4'S,5'S,6'R)-6-[(4-Ethylphenyl)methyl]-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro[isobenzofuran-1(3H),2'-[2H]pyran]-3',4 ',5'-triolCSG 452, (1S,3'R,4'S,5'S,6'R)-6-[(4-Ethylphenyl)methyl]-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)-spiro[isobenzofuran-1(3H),2'-[2H]pyran]-3',4',5'-triol, (1S,3′R,4′S,5′S,6′R)-6-[(4-Ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol, Csg 452, R-7201, Spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol, 6-[(4-ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)-, (1S,3′R,4′S,5′S,6′R)-

Description

Tofogliflozin is a glucose-lowering drug that acts as an inhibitor of sodium-glucose transport (SGLT2) in the proximal tubule. It is used for the treatment of type 2 diabetes mellitus and other metabolic disorders, including hepatic impairment. Tofogliflozin has been shown to be effective for reducing systolic blood pressure in patients with hypertension. This drug also reduces histological evidence of disease activity and p-hydroxybenzoic acid levels in patients with active rheumatoid arthritis or psoriatic arthritis. Tofogliflozin has been shown to increase insulin sensitivity, which may be due to its ability to activate growth factor-β1 and GLP-1 receptors in adipose tissue.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 386.44 g/mol
• Formule: C₂₂H₂₆O₆
• Degré de pureté: Min. 95%
• Couleur/Forme: White Powder